已阅读5页,还剩17页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
WHO第961号技术报告 附件10 药品的预认证程序 2011Procedure for prequalification of pharmaceutical products1. Introduction介绍2. Glossary术语3. Purpose and principles目的和原则4. Steps of the procedure程序步骤5. Invitation for expressions of interest表达兴趣的6. Data and information to be submitted要提交的数据和信息7. Screening of dossiers submitted提交文件的筛选8. Dossier assessment文件评估9. Site inspection现场检查10. Reporting and communication of the results of the evaluation评估结果的报告和沟通11. Outcome of the prequalification procedure预认证程序的结果12. Maintenance of prequalification status预认证状态的维护13. Cost recovery成本回收14. Confidentiality undertaking保密义务15. Conflict of interest利益冲突Appendix 1附件1Flowchart of WHO prequalification of pharmaceutical products药品WHO预认证流程图Appendix 2附件2Characteristics of the prequalified pharmaceutical product to be made available for public access on the WHO web siteWHO官网上向公共开放的预认证药品信息 1. Introduction介绍The World Health Organization (WHO) provides United Nations agencies with advice on the acceptability, in principle, of pharmaceutical products for procurement by such agencies.世界卫生组织WHO向联合国机构提供根据该机构所采购药品是否可接受的建议。This activity of WHO aims to facilitate access to priority essential medicines that meet WHO-recommended norms and standards of acceptable quality. WHO undertakes a comprehensive evaluation of the quality of pharmaceutical products, based on information submitted by the manufacturers of such products or other applicants, and on an inspection of the corresponding manufacturing facilities and clinical sites. This is done through a standardized procedure which is based on WHO-recommended quality standards. The quality of pharmaceutical products is obviously crucial for the safety and efficacy of such products.WHO的本活动的目的使获得符合WHO推荐质量标准的优先基本药品的通道更方便。WHO负责基于产品生产商或其它申请人提交的信息,基于对相关生产场所和临床试验场所进行的检查,对药品的质量进行综合评估。这些活动都是根据WHO推荐质量标准的标准程序来运作的。药品质量显然对于这类药品的安全性和有效性非常关键。The pharmaceutical products found to meet the WHO-recommended quality standards are included in the list of medicines, as manufactured at the specified manufacturing sites, which are considered to be acceptable, in principle, for procurement by United Nations agencies. The list of prequalified pharmaceutical products is principally intended for use by United Nations agencies including the Joint United Nations Programme on HIV/AIDS (UNAIDS), United Nations Childrens Fund (UNICEF) and United Nations Population Fund (UNFPA) to guide their procurement decisions. The growing list of pharmaceutical products that have been found to meet WHO-recommended standards may, however, also be of interest to other organizations and countries wishing to engage in the bulk procurement of pharmaceutical products.所有被发现符合WHO推荐质量标准的药品均包括在药品清单中,包括其指定的生产场所,这些生产场所均被认为是可以接受的。这些清单中的药品供联合国机构采购选用。通过预认证的产品的清单原则上来说是供联合国机构使用的-包括联合国爱滋病规划署(UNAIDS)、联合国儿童基金(UNICEF)和联合国人口基金(UNFPA)-指导其采购决策。逐渐增加的符合WHO推荐标准的药品清单可能也会对其它组织和国家有益,这些国家可能会希望参与批量采购药品。Inclusion in the list does not imply any approval by WHO of the pharmaceutical products and manufacturing sites in question (which is the sole prerogative of national authorities). Moreover, inclusion in the list does not constitute an endorsement or warranty by WHO of the fitness of any product for a particular purpose, including its safety and/or efficacy in the treatment of specific diseases.药品和生产场所包括在清单中并不意味着被WHO批准(那是国家药监机构专有的权利)。并且,包括在清单中并不表示WHO保证其所有产品对特殊目的的适用性,包括其在治疗特定疾病时的安全性和/或有效性。2. Glossary术语The definitions given below apply to the terms used in this procedure. They may have different meanings in other contexts.以下给出的定义适用于本程序中所用的术语。在其它上下文中可能有不同含义。active pharmaceutical ingredient (API)活性药物成分A substance used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in human beings.活性药物成分:用于制剂成品的一种物质,具有药物活性,或对诊断、治愈、缓解或预防疾病有直接影响,或对恢复、纠正或修复人类生理功能产生直接作用。Applicant申请人The person or entity who, by the deadline mentioned in the invitation, submits an expression of interest (EOI) to participate in this procedure in respect of the product(s) listed in the invitation, together with the required documentation on such product(s).在期限前,提交EOI表达想要参与产品预认证程序,并提交本程序所需的文件的人或实体。contract research organization (CRO)合同研发组织(CRO)An organization (commercial, academic or other) to which an applicant may have transferred some of its tasks and obligations in relation to the conduct of clinical studies with the product submitted to WHO for assessment under the current procedure.合同研发组织:接受申请人可能将要提交WHO作预认证的产品中,有些与临床研究有关的任务或义务外包的组织(商业、学术或其它)。finished pharmaceutical product (FPP)制剂产品A finished dosage form of a pharmaceutical product, which has undergone all stages of manufacture, including packaging in its final container and labelling.制剂产品:已完成所有生产步骤,包括最终包装和标签的制剂成品。invitation for expressions of interest (EOIs) or invitation表达兴趣的邀请Invitation calling upon interested parties (e.g. manufacturers or other applicants) to submit an expression of interest (EOI) to WHO by a specified deadline for the purpose of participating in the WHO prequalification procedure in respect of the product(s) listed in the invitation. Such an EOI should be accompanied by the required documentation on the product(s) in question. 表达兴趣的邀请:召集有兴趣组织(例如,生产商或其它申请人),根据WHO列在邀请中的产品,在指定的期限前向WHO提交表示其兴趣,以参与WHO预认证程序。该EOI应与涉及产品所需的资料一起提交。Manufacturer生产商A company that produces, packages, repackages, labels and/or relabels pharmaceutical products.生产商:一个生产、包装、再包装、标签和/或再标签药品的公司。pharmaceutical product药品Any substance or combination of substances marketed or manufactured to be marketed for treating or preventing disease in human beings, or with a view to making a medical diagnosis in human beings, or to restoring, correcting or modifying physiological functions in human beings.药品:所有销售或生产准备销售的物质或物质混合物,用于治疗或防止人类疾病,或诊断人类疾病,或恢复、纠正或修复人类的生理功能。Prequalification预认证Standardized quality assessment procedure of WHO to evaluate the acceptability, in principle, of pharmaceutical products for purchase by United Nations agencies. Agencies using information resulting from the prequalification procedure should perform additional steps of qualification prior to purchasing, such as ensuring financial stability and standing of the supplier, ability to supply the required quantities, security of the supply chain, preshipment quality control and other related aspects.预认证:WHO的标准质量评估程序,用于评价联合国机构所采购的药品的可接受性。机构在使用这些通过预认证收集的信息前,要另外采取一些确认措施,例如确认经济稳定性、供应商的立场、供应所需数量的能力、供应链的安全性、发货前质量控制和其它相关方面。stringent regulatory authority (SRA)For the purpose of this procedure, a stringent regulatory authority (SRA) is:严格法规机构:本程序下,严格法规机构指 the medicines regulatory authority in a country which is: (a) a member of the International Conference on Harmonisation (ICH) (European Union (EU) Japan and the United States of America); or (b) an ICH Observer, being the European Free Trade Association (EFTA) as represented by SwissMedic and Health Canada (as may be updated from time to time); or (c) a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time); and 国家药品法规机构是:(a)是ICH成员之一(欧盟、日期和美国),或(b)ICH观察员,是欧洲自由贸易联盟EFTA由瑞士药监和加拿大药监代表(可能会随时更新),或(c)通过合法联系、共认协议与ICH成员协作的药监局,包括澳大利亚、冰岛、里兹本、挪威(可能会随时更新),以及 only in relation to good manufacturing practices (GMP) inspections: a medicine regulatory authority that is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) as specified at. 仅与GMP检查相关:药品法规当局是PIC/S组织的成员之一3. Purpose and principles目的和原则The purpose of this WHO procedure is to evaluate whether certain pharmaceutical products (considered by WHO to be vital for the prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), tuberculosis, malaria and other diseases, or for reproductive health) meet the requirements recommended by WHO and are manufactured in compliance with current good manufacturing practices (hereinafter referred to as GMP).本WHO程序的目的是评估特定的药品(WHO认为治疗艾滋病、肺结核、疟疾和其它疾病,或生殖健康必须的药物)是否符合由WHO推荐的要求,是否在符合GMP的条件下生产。This procedure established by WHO is based on the following principles:本程序由WHO建立,基于以下原则 the medicines eligible for prequalification are listed in invitations for EOI published on the WHO web site (/prequal/info_applicants/info_for_applicants_EOIs.htm); 适合预认证的药品在WHO官网上公布的EOI邀请中列出 a general understanding of the production and quality control activities of the manufacturer; 对生产商的生产和质量控制活动的共同了解 assessment of pharmaceutical product data and information on safety, efficacy and quality submitted by the manufacturer, including product formulation, manufacture and test data and results; 对生产商提交的药品安全、有效性和质量的数据和信息进行评估,包括产品配方、生产和检测数据和结果 inspection of finished pharmaceutical product (FPP) and active pharmaceutical ingredient (API) manufacturing site(s) for compliance with GMP; 对原料药和制剂生产场所GMP符合性的检查 inspection of clinical testing units or contract research organizations (CROs) performing clinical trials for compliance with current good clinical practices (hereinafter referred to as GCP) and current good laboratory practices (hereinafter referred to as GLP); 对实施临床研究的临床试验单位或合同研究机构(CROs)进行GCP和GLP符合性检查 reliance on the information supplied by stringent national medicines regulatory authorities; 依赖由严格国家药监机构提供的信息 random sampling and testing of pharmaceutical products supplied; 对供货的药品进行随机抽样和检测 handling of complaints and recalls reported to WHO; and 处理报告至WHO的客诉和召回,以及 monitoring of complaints from agencies and countries. 药监机构和国家对客诉的监控WHO may collaborate with national medicines regulatory authorities (NMRAs) regarding dossier assessments and inspections. Subject to the terms of section 4 below, the prequalification of a product may also be based on approval by a stringent regulatory authority (SRA).WHO可能与国家药监局(NMRA)一起进行对产品资料的评审和现场检查。根据以下第4部分的情况,产品预认证也可以基于严格法规机构的批准。WHO recommends that applicants expressing interest in participation in the prequalification procedure inform the NMRAs in the country of manufacture of their intention and request them to collaborate with WHO in the quality assessment process. It is recommended that applicants provide the NMRAs with the necessary authorization to discuss the relevant product files with WHO representatives during dossier assessment and site inspections (subject to appropriate confidentiality provisions, if necessary).WHO推荐申请人将表达要参与预认证程序的情况通知其生产所在国的NMRA,要求他们与WHO合作进行质量评审过程。建议申请人向NFRA提供必要的授权,在资料评审过程中与WHO代表讨论相关产品资料,并参与现场检查(必要时,服从适当的保密条款)。4. Steps of the procedure程序步骤WHO undertakes a comprehensive evaluation of the quality of pharmaceutical products, based on information submitted by the applicants, and inspection of the relevant manufacturing and clinical sites. (A flowchart showing the prequalification process is provided in Appendix 1.)基于申请人提交的资料,WHO对药品的质量进行综合评估,对相关的生产和临床试验场所进行现场检查。(预认证流程图见附件1)At regular intervals, and also taking into consideration pertinent input received from relevant United Nations agencies, WHO will publish an invitation to interested parties, requesting them to voluntarily participate in this procedure in respect of the products mentioned in the invitation.WHO定期,同时考虑其所收到的来自相关联合国机构的信息,向有兴趣的组织公布邀请,请求他们自愿参与本程序,进入邀请中提到产品的预认证程序。By submitting an EOI, the applicant undertakes to share information with WHO on all relevant aspects of manufacture and control of the specified products along with changes made and/or planned. Interested applicants provide the necessary information to WHO by submitting a product dossier in the prescribed format, and other information as requested.申请人提交EOI,表示愿意与WHO共享所有与指定药品相关的生产和控制的信息,以及做出的变更和/或计划的变更。有兴趣的申请人通过按指定的格式提交产品资料和其它要求的信息,向WHO提供必要的信息。The procedure will normally include:程序一般包括: assessment of product dossiers, which must include product data and information as specifi ed in the guidelines for submission, available on the WHO web site (/prequal/); 对产品资料的评估,资料中必须包括在申报指南中列出的产品数据和信息,在WHO官网上可以找到 inspection of manufacturing sites of FPPs and active pharmaceutical ingredients (APIs), to assess compliance with GMP; 对制剂和原料药的生产场所进行检查,以对其GMP符合性进行评估 inspection of clinical sites (if applicable), to assess compliance with GCP and GLP as appropriate. 对临床试验场所(如适用)进行检查,评估GCP和GLP的符合性If the evaluation above demonstrates that a product and its corresponding manufacturing (and clinical) site(s) meet WHO-recommended standards, the product will be included in the list of pharmaceutical products that are considered to be acceptable, in principle, for procurement by United Nations agencies.如果上述评估证明产品和其相应的生产(和临床试验)场所符合WHO推荐的标准,则该产品会被放入可以接受的药品清单中,原则上,供联合国机构采购。WHO reserves the right to terminate the evaluation of a specific product if the applicant is not able to provide the required information, and/or is unable to implement any corrective actions which WHO may require within a specified time period, or when the information supplied is inadequate to complete this procedure.如果申请人不能提供所要求的信息,和/或不能实施所有的WHO可能会要求在一定时间完成的纠正措施,或者提供的信息不充分,使得程序无法完成,WHO保留权利中止对该产品的评估。WHO recognizes the evaluation of relevant products by SRAs which apply standards for quality equivalent to those recommended by WHO. Provided that the NMRA is willing to share certain information with WHO on the products in question, WHO will consider such products for inclusion in the list of WHO-prequalified products. It will do so as and when information about such products becomes available to WHO and when the holders of the regulatory approval of such products express their interest in having these products prequalified by WHO. These products will be added to the list of products prequalified by WHO, on the basis of the scientific assessment and inspections conducted by the regulatory authority concerned, and the exchange of relevant information between the regulatory authority and WHO.WHO知道由SRA对相关产品进行的评估所适用的质量标准与WHO推荐的其实是等同的,如果NMRA愿意与WHO分享所讨论产品的特定信息,WHO会考虑将这些产品直接列入WHO预认证产品清单。如果WHO可以获得这些信息,这类产品的法规批准持有人表达其想要WHO对这些产品进行预认证的兴趣,则WHO就可以进行上述操作。在所在国家药监当局对该药品进行科学性评审,实施现场检查,并且该国家药监当局与WHO交换相关信息的基础上,这些药品会被加入WHO预认证的产品清单中。An inspection of a manufacturer or CRO may not be required if:如果满足以下条件,可能不需要对生产商或CRO进行检查1. There has been an inspection by an SRA; and由SRA检查过,以及2. The inspection was conducted within the last three years; and检查是在最近三年内进行的,以及3. Information on the inspection (including inspection report and responses to any deficiencies) is available for review by WHO; andWHO可以审核检查信息(包括检查报告和对所有缺陷的回复),以及4. Based on this and other available information, it is determined1 that the site(s) in question meet(s) the applicable WHO-recommended standards.基于此和其它可以获得的信息,决定所讨论的工厂符合WHO推荐的适用标准。With a view to coordinating inspection activities, avoiding duplication and promoting information sharing without prejudice to the protection of any confidential and or proprietary information of the applicants and manufacturers in accordance with the terms of this procedure, WHO may disclose inspection related information to regulatory authorities of WHO Member States as well as to regulatory authorities that are members of the PIC/S.在协调检查活动时,根据本程序的相关规定,为避免重复检查,无偏见地共享信息,保护申请人和生产商的知识产权,WHO会将检查相关的信息共享给WHO成员国药监机构、是PIC/S成员的药监机构。5. Invitation for expressions of interest表达兴趣的邀请The pharmaceutical products listed in an invitation for EOIs are considered by WHO to be vital for the effective treatment and prevention of the specified diseases (including HIV/AIDS, malaria and tuberculosis) or for reproductive health. These products are normally included in either the WHO Model List of Essential Medicines or the relevant WHO treatment guidelines and recommendations (or both).在EOI邀请中列出的药品是WHO认为对某些特定疾病(包括艾滋病、疟疾和肺结核)或生殖健康进行治疗和预防所必须的药品。这些药品一般包括在WHO基本药物清单中,或者包括在WHO相关的治疗指南和建议中(或两者中均包括)。The products included in the WHO Model List of Essential Medicines are those that satisfy the priority health-care needs of a population. They are selected, among other criteria, on the basis of disease prevalence, evidence on efficacy and safety, and analysis of comparative cost-effectiveness. Products included in WHO treatment guidelines are selected on the basis of an assessment of the evidence for benefits, risks, costs and appropriateness for use in a variety of situations, taking into account the needs of special populations and the values and preferences of the groups (professional and patient) using them.包括在WHO基本药物清单里的产品是满足人口基本健康的药品。它们是在疾病流行程度、有效性和安全性证据、性价比分析基础上,从其它标准中选出来的。包括在WHO治疗指南中的产品是在对利益、风险、成本和不同情况下使用的适当性的证据评估基础上选择的,同时考虑了特殊人群的需要,价值和使用它们的专业人士和病人组的优先情况。Each invitation will be open and transparent, inviting all relevant parties to submit an EOI for the pharmaceutical products listed. Such an invitation will normally be published on the WHO web site and possibly also through other media, such as the international press.每个邀请都是公开透明的,邀请所有相关方提交列出产品的EOI。这种邀请一般在WHO官网上公布,也可以通过其它媒体,例如国际出版物找到。In situations of high public health concern as determined by WHO, the Organization may also directly invite relevant parties to submit specified product dossiers for evaluation by WHO under this procedure without publication of an invitation for EOI.如果WHO认为情况为公众健康相关性特别高,则组织也可能直接邀请相关方提交指定产品文件,由根据本程序WHO进行评估,而不公开EOI邀请。6. Data and information to be submitted要提交的数据和信息Interested parties are expected to submit documentation on the pharmaceutical products as called for in the invitation for EOIs. Applicants should submit their product dossiers with the required information to the WHO focal point, before the deadline specified in the invitati
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2026年国际货运考试题库及参考答案
- 2026年仪器仪表技术试题库带答案
- 2026年物业竞岗笔试题库及参考答案
- 2026年衣物收纳考试题库带答案
- 2026年药剂师笔试题库带答案
- 浆砌石护岸松动块石重新砌筑方案
- 既有建筑钢筋锈蚀除锈环氧砂浆修补施工方案
- 露营户外损伤预防专家共识(2026版)
- 2027届新疆乌鲁木齐水磨沟区四校联考中考物理五模试卷含解析
- 2027年备考临床医师强化训练试题卷附答案
- DB61∕T 1486.4-2021 设施茄果类蔬菜水肥一体化技术规范 第4部分:番茄越冬长季节基质栽培
- 湖北省仙桃、天门、潜江市2025-2026学年高一上化学期中联考试题含解析
- DG-TJ08-2478-2025 装配式混凝土预制构件设计一生产数据交互标准
- 医院供应室去污区操作规范
- 进线柜保护培训课件
- 低压线损管理办法
- GB/T 45743-2025生物样本细胞运输通用要求
- JG/T 158-2013胶粉聚苯颗粒外墙外保温系统材料
- 鞍区肿瘤护理
- T-NXJX-028控制阀检维修规范
- 海口市地下综合管廊试点工程终稿
评论
0/150
提交评论